Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors Academic Article uri icon


MeSH Major

  • Antineoplastic Agents
  • Benzamides
  • Bone Density
  • Bone Resorption
  • Gastrointestinal Stromal Tumors
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Osteogenesis
  • Piperazines
  • Pyrimidines


  • Patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumors (GIST) who take imatinib have abnormalities of bone metabolism. However, it is unclear what impact these changes have on bone mineral density (BMD). We prospectively analayzed levels of osteocalcin, a marker of bone formation secreted by osteoblasts, and serum N-telopeptide of type I collagen (NTX), a marker of bone resorption, as well as other minerals involved in bone metabolism in 19 patients with either CML or GIST We correlated these results with changes in bone mineral density as measured by serial dual energy X-ray absorptiometry (DEXA) scans over a two year period. Osteocalcin levels were low in 95% of patients and 37% had no measurable amount. Levels of NTX were less consistent. Nine patients (47%) had a decrease in BMD, four patients (2%) had an increase in BMD, and six patients (32%) had no change. There was no correlation between metabolic markers and change in BMD. We suggest that ongoing management of patients who take imatinib should include monitoring of bone health on a long term basis.

publication date

  • July 2013



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2013.02.005

PubMed ID

  • 23473999

Additional Document Info

start page

  • 790

end page

  • 4


  • 37


  • 7